Katherine h Campbell

Dr. Katherine h Campbell


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HHHillary Hosier
Hillary Hosier
SFShelli F. Farhadian
Shelli F. Farhadian
RMRaffaella A. Morotti
Raffaella A. Morotti
UDUma Deshmukh
Uma Deshmukh
ALAlice Lu-Culligan
Alice Lu-Culligan
HLHeather S. Lipkind
Heather S. Lipkind
BACKGROUND. The effects of the novel coronavirus disease 2019 (COVID-19) in pregnancy remain relatively unknown. We present a case of second trimester pregnancy with symptomatic COVID-19 complicated by severe preeclampsia and placental abruption. METHODS. We analyzed the placenta for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) through molecular and immunohistochemical assays and by and electron microscopy and measured the maternal antibody response in the blood to this infection. RESULTS. SARS–CoV-2 localized predominantly to syncytiotrophoblast cells at the materno-fetal interface of the placenta. Histological examination of the placenta revealed a dense macrophage infiltrate, but no evidence for the vasculopathy typically associated with preeclampsia. CONCLUSION. This case demonstrates SARS–CoV-2 invasion of the placenta, highlighting the potential for severe morbidity among pregnant women with COVID-19. FUNDING. Beatrice Kleinberg Neuwirth Fund and Fast Grant Emergent Ventures funding from the Mercatus Center at George Mason University. The funding bodies did not have roles in the design of the study or data collection, analysis, and interpretation and played no role in writing the manuscript.

1 September 2013 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
KCKatherine h Campbell
Katherine h Campbell
DSDavid Savitz
David Savitz
EWErika F. Werner
Erika F. Werner
CPChristian M. Pettker
Christian M. Pettker
DGDena Goffman
Dena Goffman
HLHeather S. Lipkind
Heather S. Lipkind
OBJECTIVE: To examine the effect of underlying maternal morbidities on the odds of maternal death during delivery hospitalization. METHODS: We used data that linked birth certificates to hospital discharge diagnoses from singleton live births at 22 weeks of gestation or later during 1995–2003 in New York City. Maternal morbidities examined included prepregnancy weight more than 114 kilograms (250 pounds), chronic hypertension, pregestational or gestational diabetes mellitus, chronic cardiovascular disease, pulmonary hypertension, chronic lung disease, human immunodeficiency virus (HIV), and preeclampsia or eclampsia. Associations with maternal mortality were estimated using multivariate logistic regression. RESULTS: During the specified time period, 1,084,862 live singleton births and 132 maternal deaths occurred. Patients with increasing maternal age, non-Hispanic black ethnicity, self-pay or Medicaid, primary cesarean delivery, and premature delivery had higher rates of maternal mortality during delivery hospitalization. From the entire study population, 4.1% had preeclampsia or eclampsia (n=44,004), 1.8% had chronic hypertension (n=19,647), 1.1% of patients were classified as obese (n=11,936), 0.7% had pregestational diabetes (n=7,474), 0.4% had HIV (n=4,665), and 0.01% had pulmonary hypertension (n=166). Preeclampsia or eclampsia (adjusted odds ratio [OR], 8.1; 95% confidence interval [CI], 5.5–12.1), chronic hypertension (adjusted OR, 7.7; 95% CI 4.7–12.5), underlying maternal obesity (adjusted OR, 2.9; 95% CI 1.1–8.1), pregestational diabetes (adjusted OR, 3.3; 95% CI 1.3–8.1), HIV (adjusted OR, 7.7; 95% CI 3.4–17.8), and pulmonary hypertension (adjusted OR, 65.1; 95% CI 15.8–269.3) were associated with an increased risk of death during the delivery hospitalization. CONCLUSION: The presence of maternal disease significantly increases the odds of maternal mortality at the time of delivery hospitalization. LEVEL OF EVIDENCE: II

23 June 2020 in JAMA
Verified
Journal Article
Open access
PDF file
KCKatherine h Campbell
Katherine h Campbell
JTJean M. Tornatore
Jean M. Tornatore
KLKirsten E. Lawrence
Kirsten E. Lawrence
JIJessica L. Illuzzi
Jessica L. Illuzzi
LSL. Scott Sussman
L. Scott Sussman
CPChristian M. Pettker
Christian M. Pettker
Developing an approach to care for pregnancy and childbirth during the coronavirus disease 2019 (COVID-19) crisis is a priority to (1) provide safe care to pregnant women and newborns; and (2) protect health care workers from infection. A study conducted in New York City reported a 13.5% prevalence of asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in women presenting for childbirth.1 On March 30, 2020, an initially asymptomatic woman admitted to the Yale New Haven Health system developed cough and fever soon after childbirth; testing confirmed SARS-CoV-2 infection. This event prompted the development of a SARS-CoV-2 screening and testing program of patients presenting for childbirth; we report the prevalence detected in the first weeks of the program.

1 January 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
XXXiao Xu
Xiao Xu
HLHenry Lee
Henry Lee
HLHaiqun Lin
Haiqun Lin
LLLisbet S. Lundsberg
Lisbet S. Lundsberg
KCKatherine h Campbell
Katherine h Campbell
JIJessica L. Illuzzi
Jessica L. Illuzzi

24 September 2018 in Birth
Verified
Journal Article
Closed access
PDF file
KCKatherine h Campbell
Katherine h Campbell
JIJessica L. Illuzzi
Jessica L. Illuzzi
HLHenry C. Lee
Henry C. Lee
HLHaiqun Lin
Haiqun Lin
HLHeather S. Lipkind
Heather S. Lipkind
XXXiao Xu
Xiao Xu

26 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ALAlice Lu-Culligan
Alice Lu-Culligan
ACArun R. Chavan
Arun R. Chavan
PVPavithra Vijayakumar
Pavithra Vijayakumar
LILina Irshaid
Lina Irshaid
ECEdward M. Courchaine
Edward M. Courchaine
SFShelli F. Farhadian
Shelli F. Farhadian
Pregnant women appear to be at increased risk for severe outcomes associated with COVID-19, but the pathophysiology underlying this increased morbidity and its potential impact on the developing fetus is not well understood. In this study of pregnant women with and without COVID-19, we assessed viral and immune dynamics at the placenta during maternal SARS-CoV-2 infection. Amongst uninfected women, ACE2 was detected by immunohistochemistry in syncytiotrophoblast cells of the normal placenta during early pregnancy but was rarely seen in healthy placentas at full term. Term placentas from women infected with SARS-CoV-2, however, displayed a significant increase in ACE2 levels. Using immortalized cell lines and primary isolated placental cells, we determined the vulnerability of various placental cell types to direct infection by SARS-CoV-2 in vitro . Yet, despite the susceptibility of placental cells to SARS-CoV-2 infection, viral RNA was detected in the placentas of only a subset (∼13%) of women in this cohort. Through single cell transcriptomic analyses, we found that the maternal-fetal interface of SARS-CoV-2-infected women exhibited markers associated with pregnancy complications, such as preeclampsia, and robust immune responses, including increased activation of placental NK and T cells and increased expression of interferon-related genes. Overall, this study suggests that SARS-CoV-2 is associated with immune activation at the maternal-fetal interface even in the absence of detectable local viral invasion. While this likely represents a protective mechanism shielding the placenta from infection, inflammatory changes in the placenta may also contribute to poor pregnancy outcomes and thus warrant further investigation.